A Study to Evaluate the Safety and Efficacy of Paltusotine for the Treatment of Acromegaly (PATHFNDR-2)
Status:
Recruiting
Trial end date:
2025-08-01
Target enrollment:
Participant gender:
Summary
A randomized, placebo-controlled study designed to evaluate the safety and efficacy of
paltusotine (formerly CRN00808; an oral selective nonpeptide somatostatin receptor type 2
biased agonist) in subjects with non-pharmacologically treated acromegaly.